Large Cap Biotechnology
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
26
Summit Therapeutics
SMMT
$10.7B
| $10.7B | $13.36 | 4.95% |
|
27
Ionis Pharmaceuticals
IONS
$10.6B
| $10.6B | $63.57 | 2.47% |
|
28
Krystal Biotech
KRYS
$10.5B
| $10.5B | $356.19 | 4.23% |
|
29
Kymera Therapeutics
KYMR
$10.5B
| $10.5B | $126.64 | 4.62% |
|
|
ABVX
30
Abivax
ABVX
$10.3B
| $10.3B | $117.93 | 1.53% |
|
31
Praxis Precision Medicines
PRAX
$10.3B
| $10.3B | $368.02 | 0% |
|
32
Apogee Therapeutics
APGE
$10.2B
| $10.2B | $134.85 | 0.04% |
|
Large Cap Biotechnology Stocks at a Glance
Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.
There are 32 large cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $10B and $200B — worth a combined $862B.
The largest by market cap are Vertex Pharmaceuticals (VRTX) at $140B, Regeneron Pharmaceuticals (REGN) at $85.8B and argenx (ARGX) at $63.8B.
Among institutional investors, Revolution Medicines (RVMD) drew the most net new fund positions in Q2 2026: 243 funds opened new positions, taking total fund holders up 176 (34%) quarter-over-quarter.
- Combined market cap: $862B across 32 stocks.
- Large Cap: market cap between $10B and $200B.
- Largest constituent: Vertex Pharmaceuticals (VRTX), $140B market cap.
- Most net new fund positions in Q2 2026: Revolution Medicines (RVMD), +176 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.